David Marcilla
Overview
Explore the profile of David Marcilla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hindi N, Carrasco Garcia I, Sanchez-Camacho A, Gutierrez A, Peinado J, Rincon I, et al.
Cancers (Basel)
. 2020 Dec;
12(12).
PMID: 33322663
Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical...
12.
Martin-Broto J, Cruz J, Penel N, Cesne A, Hindi N, Luna P, et al.
Lancet Oncol
. 2020 Feb;
21(3):456-466.
PMID: 32066540
Background: Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib...
13.
Rodriguez-Nunez P, Romero-Perez L, Amaral A, Puerto-Camacho P, Jordan C, Marcilla D, et al.
J Pathol
. 2019 Dec;
250(4):374-386.
PMID: 31880317
YAP1 and TAZ (WWTR1) oncoproteins are the final transducers of the Hippo tumor suppressor pathway. Deregulation of the pathway leads to YAP1/TAZ activation fostering tumorigenesis in multiple malignant tumor types,...
14.
Diaz-Martin J, Biscuola M, Benoit J, Marcilla D, Civantos G, de Alava E
J Pathol
. 2018 Nov;
247(4):409-412.
PMID: 30474142
This commentary addresses the issue of the classification of sarcomas in the article written by Watson and colleagues published recently in this journal. The article delves into the molecular characterization...
15.
Machado I, Pozo J, Marcilla D, Cruz J, Tardio J, Astudillo A, et al.
Rev Esp Patol
. 2017 Nov;
50(1):34-44.
PMID: 29179963
Primary bone neoplasms represent a rare and heterogeneous group of mesenchymal tumours. The prevalence of benign and malignant tumours varies; the latter (sarcomas) account for less than 0.2% of all...
16.
Hontecillas-Prieto L, Garcia-Dominguez D, Vaca D, Garcia-Mejias R, Marcilla D, Ramirez-Villar G, et al.
Oncotarget
. 2017 Oct;
8(38):64652.
PMID: 28969102
[This corrects the article DOI: 10.18632/oncotarget.14491.].
17.
Vallejo-Benitez A, Rodriguez-Zarco E, Carrasco S, Pereira-Gallardo S, Brugal Molina J, Garcia-Escudero A, et al.
Ann Diagn Pathol
. 2017 Oct;
30:8-11.
PMID: 28965630
DOG1 is a highly-sensitive marker often included in the immunohistochemical panel for the diagnosis of gastrointestinal stromal tumors (GISTs). Recent research has shown that DOG1 may also be expressed by...
18.
Hontecillas-Prieto L, Garcia-Dominguez D, Vaca D, Garcia-Mejias R, Marcilla D, Ramirez-Villar G, et al.
Oncotarget
. 2017 Jan;
8(7):11173-11186.
PMID: 28061436
Wilms tumour (WT) is the most common renal tumour in children. Most WT patients respond to chemotherapy, but subsets of tumours develop resistance to chemotherapeutic agents, which is a major...
19.
de Alava E, Marcilla D
Semin Diagn Pathol
. 2016 Jun;
33(5):254-61.
PMID: 27312937
The first large series of desmoplastic small round cell tumor was reported twenty-five years ago. This article reviews the original characterization of this neoplasm, and the eventual expansion of its...
20.
Fernandez-Pineda I, Marcilla D, Downey-Carmona F, Roldan S, Ortega-Laureano L, Bernabeu-Wittel J
Ann Vasc Dis
. 2014 Oct;
7(3):316-9.
PMID: 25298836
The acronym FAVA (Fibro-Adipose Vascular Anomaly) has been recently given to a distinct vascular entity that is characterized by fibrofatty infiltration of muscle, unusual phlebectasia with pain, and contracture of...